Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Equinor ASA (EQNR) vs Medpace Holdings Inc (MEDP) Price & Performance

Equinor ASATrade
Medpace Holdings IncTrade

Price performance (Past 24H)

Key statistics

Equinor ASA vs Medpace Holdings Inc — how do they compare? Equinor ASA trades at $40.95 (market cap $97.58B), while Medpace Holdings Inc trades at $601.1 (market cap $16.90B). The key difference: Equinor ASA is far larger — about 5.8× Medpace Holdings Inc's market cap, and Equinor ASA pays a 3.81% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.

EQNRMEDP
Market Cap
$97.58B$16.90B
Sector
EnergyTechnology
52-Week High
$42.40$620.59
52-Week Low
$22.41$393.42
Enterprise Value
$106.28B$16.52B
Dividend Yield
3.81%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Equinor ASA

Equinor (EQNR) trades at $40.865, down 0.3% on the day, with a bullish technical signal from moving averages. The company reported mixed Q2 2026 earnings, missing EPS estimates but showing strong revenue growth of 40% year-over-year. Valuation ratios remain attractive with a P/E of 11.09 and EV/EBITDA of 2.3. Recent news highlights a 22.2% monthly rally, driven by higher energy prices and output, alongside ongoing share buybacks and consistent dividend payments.

The outlook is cautiously positive, supported by robust cash flow and strategic investments in production growth. However, risks include volatile energy prices, execution challenges in portfolio adjustments, and a high tax burden impacting net margins. Analyst sentiment is mixed, with 30% buy ratings but majority holds, reflecting valuation concerns after recent gains.

Medpace Holdings Inc

MEDP trades at $600.00, down 0.4% on the day, with a bullish technical signal driven by moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $4.25, and raised full-year guidance. Revenue growth is robust, with 2026 projected at $2.8 billion, though valuation multiples like a P/E of 35.58 and P/B of 38.95 are elevated. Net cash flow is expected to turn positive in 2026, and institutional activity is mixed, with some funds increasing stakes while others trim positions.

Outlook is positive due to earnings momentum and record bookings, but risks include high valuation sensitivity and a shareholder lawsuit investigation. Analyst consensus is a $599.57 price target with a 'Hold' bias, suggesting limited near-term upside from current levels amid growth-priced expectations.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Equinor ASA

Equinor is a Norway-based integrated oil and gas company. It has been publicly listed since 2001, but the government retains a 67% stake. Operating primarily on the Norwegian Continental Shelf, the firm produced 2.1 million barrels of oil equivalent per day in 2021 (52% oil) and ended the year with 5.4 billion barrels of proven reserves (49% oil). Operations also include offshore wind, solar, oil refineries and natural gas processing, marketing, and trading.

Read more on EQNR

About Medpace Holdings Inc

Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.

Read more on MEDP